Product Information
Registration Status: ActiveHUMIRA
HUMIRA SOLUTION FOR INJECTION 80MG/0.8ML (PREFILLED PEN) is approved to be sold in Singapore with effective from 2020-03-19. It is marketed by ABBVIE PTE LTD, with the registration number of SIN15914P.
This product contains Adalimumab 80mg/0.8mL in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Vetter Pharma-Fertigung GmbH & Co. KG (Schützenstrasse) in GERMANY, andAbbVie Biotechnology Ltd (ABL) in UNITED STATES.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons [L1306].
Indication
For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Mechanism of Action
Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.
Clearance
* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]
Active Ingredient/Synonyms
Adalimumab (genetical recombination) | adalimumab-adbm | adalimumab-atto | Adalimumab |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.